相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
Nicholas G. LaRocca et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
Nicholas G. LaRocca et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Carmen Tur et al.
NATURE REVIEWS NEUROLOGY (2018)
Continuous daily assessment of multiple sclerosis disability using remote step count monitoring
V. J. Block et al.
JOURNAL OF NEUROLOGY (2017)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
Diego Cadavid et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
Diego Cadavid et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Remotely engaged: Lessons from remote monitoring in multiple sclerosis
Matthew M. Engelhard et al.
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis
Laura J. Balcer et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Clinical outcome measures for progressive MS trials
Daniel Ontaneda et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Remyelination therapies: a new direction and challenge in multiple sclerosis
Jason R. Plemel et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials
Maria Pia Sormani et al.
NEUROTHERAPEUTICS (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis
Laura J. Balcer et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Clinical outcome measures for progressive MS trials
Daniel Ontaneda et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
Bruno Brochet et al.
PLOS ONE (2017)
Comparative utility of disability progression measures in PPMS Analysis of the PROMiSe data set
Marcus W. Koch et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Outcome Measures in Clinical Trials for Multiple Sclerosis
Caspar E. P. van Munster et al.
CNS DRUGS (2017)
Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses
Aseel Bin Sawad et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Relapses in multiple sclerosis: Relationship to disability
Douglas S. Goodin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review
Valerie A. J. Block et al.
PLOS ONE (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Remote cognitive assessments for patients with multiple sclerosis: a feasibility study
Jill R. Settle et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis A Randomized Clinical Trial
Jeffrey Cohen et al.
JAMA NEUROLOGY (2015)
Remote cognitive assessments for patients with multiple sclerosis: a feasibility study
Jill R. Settle et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan
Richard A. Rudick et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
Omar Khan et al.
ANNALS OF NEUROLOGY (2013)
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Fred D. Lublin et al.
ANNALS OF NEUROLOGY (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Giancarlo Comi et al.
ANNALS OF NEUROLOGY (2011)
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
M. S. Freedman et al.
NEUROLOGY (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
New perspectives in the natural history of multiple sclerosis
Helen Tremlett et al.
NEUROLOGY (2010)
The Multiple Sclerosis Functional Composite A clinically meaningful measure of disability
Chris H. Polman et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Economic Burden of Multiple Sclerosis A Systematic Review of the Literature
Huseyin Naci et al.
PHARMACOECONOMICS (2010)
The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature
Huseyin Naci et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis
Myla D. Goldman et al.
Therapeutic Advances in Neurological Disorders (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Historical and clinical perspectives of the expanded disability status scale
John F. Kurtzke
NEUROEPIDEMIOLOGY (2008)
'Restricting choices and limiting independence': social and economic impact of multiple sclerosis upon households by level of disability
G. Green et al.
CHRONIC ILLNESS (2008)
Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis:: a randomized placebo controlled multicentre study
D. Poehlau et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment
C Confavreux et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2006)
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
O Andersen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial
OR Hommes et al.
LANCET (2004)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Relapses and progression of disability in multiple sclerosis.
C Confavreux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Linomide in relapsing and secondary progressive MS - Part I: Trial design and clinical results
JH Noseworthy et al.
NEUROLOGY (2000)
Cladribine and progressive MS - Clinical and MRI outcomes of a multicenter controlled trial
GPA Rice et al.
NEUROLOGY (2000)
分享论文
